Arrowhead Pharmaceuticals' ARO-CFB Shows Promise in Treating Complement-Mediated Diseases

Arrowhead Pharmaceuticals Advances RNA Therapeutic for Complement-Mediated Diseases

Arrowhead Pharmaceuticals, Inc. announces positive interim findings from its Phase 1/2a clinical trial of ARO-CFB, an investigational RNA interference therapeutic designed to target complement factor B (CFB). This study, aimed at addressing complement-mediated diseases, reveals significant efficacy among healthy volunteers, as presented at the 8th Complement-Based Drug Development Summit in Boston on December 11, 2024. Interim results, which were collected through November 15, 2024, demonstrate that a single 400 mg dose of ARO-CFB achieves up to a 90% reduction in circulating CFB protein levels. Even more striking, the treatment shows nearly complete inhibition of alternative complement pathway activity, with 100% mean reductions observed by week four after both a 400 mg dose and two doses of 100 mg.

The implications of these findings are profound, particularly concerning diseases linked to complement system dysregulation. The long duration of response, exceeding three months, alongside dramatic reductions in metrics related to alternative pathway activation, positions ARO-CFB as a promising candidate for treating conditions such as immunoglobulin A nephropathy (IgAN), which is recognized as the most common glomerular disease worldwide. Dr. James Hamilton, Arrowhead's Chief of Discovery and Translational Medicine, expresses optimism regarding ARO-CFB's therapeutic potential as the company gears up for the next phase of its clinical study. The favorable safety profile of ARO-CFB, with no treatment-emergent adverse events leading to discontinuation, further strengthens the case for progressing to patient-focused trials.

As Arrowhead Pharmaceuticals moves forward, the completion of Part 1 of the study is anticipated in the coming months, laying the groundwork for Part 2, which will specifically target patients diagnosed with IgAN. This strategic focus aligns with the company's commitment to addressing significant unmet medical needs within the realm of complement-mediated diseases. With these promising results, Arrowhead is poised to enhance its role in the biopharmaceutical landscape, particularly in developing innovative therapies that leverage RNA interference technology.

In addition to the interim findings, the study underscores a critical advancement in understanding the complement system's role in renal diseases. By effectively inhibiting CFB, ARO-CFB has the potential to alter disease progression for patients suffering from conditions exacerbated by complement dysregulation. As Arrowhead Pharmaceuticals continues its clinical journey, the biopharmaceutical industry watches closely for further developments that could reshape therapeutic approaches to these complex diseases.